Market Closed -
Nasdaq
04:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
3.86
USD
|
+0.26%
|
|
+4.32%
|
-32.40%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10,832
|
4,027
|
2,898
|
1,657
|
1,135
|
-
|
-
|
Enterprise Value (EV)
1 |
10,240
|
3,304
|
2,012
|
1,595
|
1,015
|
1,133
|
1,095
|
P/E ratio
|
89.4
x
|
29.8
x
|
20.3
x
|
-11.2
x
|
-6.75
x
|
-6.27
x
|
-5.42
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
46.5
x
|
10.7
x
|
5.97
x
|
43.6
x
|
26.8
x
|
21.7
x
|
17.3
x
|
EV / Revenue
|
43.9
x
|
8.8
x
|
4.14
x
|
41.9
x
|
24
x
|
21.6
x
|
16.6
x
|
EV / EBITDA
|
63.7
x
|
15.1
x
|
8.23
x
|
-7.49
x
|
-4.99
x
|
-5.89
x
|
-4.34
x
|
EV / FCF
|
787
x
|
17.7
x
|
9.73
x
|
-13.2
x
|
-5.76
x
|
-7.24
x
|
-
|
FCF Yield
|
0.13%
|
5.63%
|
10.3%
|
-7.58%
|
-17.4%
|
-13.8%
|
-
|
Price to Book
|
13.1
x
|
3.84
x
|
2.36
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
269,188
|
281,581
|
286,100
|
290,170
|
294,054
|
-
|
-
|
Reference price
2 |
40.24
|
14.30
|
10.13
|
5.710
|
3.860
|
3.860
|
3.860
|
Announcement Date
|
3/29/21
|
2/24/22
|
2/21/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11.61
|
233.2
|
375.2
|
485.4
|
38.02
|
42.29
|
52.34
|
65.76
|
EBITDA
1 |
-
|
160.9
|
218.9
|
244.4
|
-212.8
|
-203.3
|
-192.5
|
-252.2
|
EBIT
1 |
-
|
156
|
204.4
|
216.5
|
-237.2
|
-231
|
-236
|
-241.1
|
Operating Margin
|
-
|
66.92%
|
54.48%
|
44.6%
|
-623.82%
|
-546.1%
|
-450.82%
|
-366.66%
|
Earnings before Tax (EBT)
1 |
-
|
157.8
|
219.1
|
239.1
|
-174
|
-188.7
|
-229.7
|
-218.4
|
Net income
1 |
-
|
118.9
|
153.5
|
158.5
|
-146.4
|
-174.7
|
-215.2
|
-218.4
|
Net margin
|
-
|
51%
|
40.9%
|
32.66%
|
-385%
|
-413.11%
|
-411.12%
|
-332.2%
|
EPS
2 |
-0.1500
|
0.4500
|
0.4800
|
0.5000
|
-0.5100
|
-0.5722
|
-0.6157
|
-0.7125
|
Free Cash Flow
1 |
-
|
13.02
|
186.1
|
206.7
|
-120.8
|
-176.4
|
-156.5
|
-
|
FCF margin
|
-
|
5.58%
|
49.61%
|
42.58%
|
-317.75%
|
-417.1%
|
-299%
|
-
|
FCF Conversion (EBITDA)
|
-
|
8.09%
|
85.04%
|
84.59%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
10.95%
|
121.29%
|
130.39%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/5/20
|
3/29/21
|
2/24/22
|
2/21/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
139.3
|
316.6
|
45.92
|
101.4
|
21.54
|
12.19
|
10.06
|
6.599
|
9.2
|
9.954
|
9.98
|
10.66
|
11.12
|
9.629
|
10.1
|
EBITDA
1 |
85.53
|
228.9
|
-3.499
|
42.88
|
-23.96
|
-59.36
|
-
|
-
|
-55.71
|
-50.05
|
-49.8
|
-48.8
|
-48.8
|
-37
|
-34.9
|
EBIT
1 |
81.55
|
225
|
-8.396
|
37.74
|
-37.78
|
-64.87
|
-51.39
|
-54.89
|
-66.05
|
-54.89
|
-57.63
|
-56.86
|
-58.23
|
-50.19
|
-51.27
|
Operating Margin
|
58.53%
|
71.06%
|
-18.29%
|
37.22%
|
-175.34%
|
-532.1%
|
-511.03%
|
-831.79%
|
-717.97%
|
-551.48%
|
-577.52%
|
-533.28%
|
-523.52%
|
-521.24%
|
-507.68%
|
Earnings before Tax (EBT)
1 |
84.71
|
230.8
|
-6.886
|
46.59
|
-31.41
|
-48.15
|
-38
|
-39.28
|
-48.6
|
-42.75
|
-46.86
|
-45.95
|
-48.1
|
-49.88
|
-55.35
|
Net income
1 |
59.95
|
168.6
|
-6.785
|
26.62
|
-29.89
|
-40.11
|
-30.53
|
-28.61
|
-47.2
|
-40.61
|
-44.29
|
-43.31
|
-46.1
|
-45.06
|
-48.65
|
Net margin
|
43.03%
|
53.25%
|
-14.78%
|
26.26%
|
-138.75%
|
-328.99%
|
-303.58%
|
-433.55%
|
-513.04%
|
-407.98%
|
-443.82%
|
-406.25%
|
-414.5%
|
-467.95%
|
-481.71%
|
EPS
2 |
0.1900
|
0.5400
|
-0.0200
|
0.0800
|
-0.1000
|
-0.1400
|
-0.1100
|
-0.1000
|
-0.1600
|
-0.1400
|
-0.1422
|
-0.1389
|
-0.1467
|
-0.1333
|
-0.1433
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/10/22
|
8/9/22
|
11/8/22
|
2/21/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/20/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
592
|
723
|
886
|
62.1
|
120
|
2
|
40.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
13
|
186
|
207
|
-121
|
-176
|
-157
|
-
|
ROE (net income / shareholders' equity)
|
-
|
28.3%
|
16.5%
|
14%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
3.080
|
3.720
|
4.300
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
0.0900
|
0.7700
|
0.8800
|
-0.2000
|
-0.2300
|
-
|
-
|
Capex
|
-
|
9.67
|
58.5
|
70.7
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
4.15%
|
15.58%
|
14.56%
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/5/20
|
3/29/21
|
2/24/22
|
2/21/23
|
2/20/24
|
-
|
-
|
-
|
Last Close Price
3.86
USD Average target price
12.71
USD Spread / Average Target +229.39% Consensus |
1st Jan change
|
Capi.
|
---|
| -32.40% | 1.14B | | +64.23% | 62.59B | | -2.31% | 41.18B | | +45.32% | 40.29B | | -8.29% | 27.9B | | +11.97% | 26.21B | | -21.16% | 19.09B | | +7.54% | 13.08B | | +27.17% | 12.05B | | +25.72% | 12.26B |
Other Biotechnology & Medical Research
|